

Amaia Calderón-Larrañaga, Beatriz Poblador-Plou, Francisca González-Rubio, Luis Andrés Gimeno-Feliu, José María Abad-Díez and Alexandra Prados-Torres

## Multimorbidity, polypharmacy, referrals, and adverse drug events:

are we doing things well?

### Abstract

#### Background

The consequences of multimorbidity include polypharmacy and repeated referrals for specialised care, which may increase the risk of adverse drug events (ADEs).

#### Aim

The objective of this study was to analyse the influence of multimorbidity, polypharmacy, and multiple referrals on the frequency of ADEs, as an indicator of therapeutic safety, in the context of a national healthcare system.

#### Design and setting

This was a multicentre, retrospective, observational study of 79 089 adult patients treated during 2008 in primary care centres.

#### Method

The explanatory patient variables sex, age, level of multimorbidity, polypharmacy, number of primary care physician visits, and number of different specialties attended were analysed. The response variable was the occurrence of ADEs. Logistic regression models were used to identify associations among the analysed variables.

#### Results

The prevalence of individuals with at least one ADE was 0.88%. Multivariate analysis identified the following variables as risk factors for the occurrence of ADE in descending order of effect size: multimorbidity level [odds ratio [OR] Veryhigh/Low = 45.26; ORHigh/Low = 17.58; ORModerate/Low = 4.25], polypharmacy [OR = 1.34], female sex [OR = 1.31], number of different specialties [OR = 1.20], and number of primary care physician visits [OR = 1.01]. Age, however, did not show statistical significance [OR = 1.00; 95% confidence interval = 0.996 to 1.005].

#### Conclusion

The results of this study demonstrate that multimorbidity is strongly related to the occurrence of ADEs, insofar as it requires the intervention of multiple specialties and the prescription of multiple medications. Further research should shed light on the causal pathway between multimorbidity and increased risk of adverse events.

#### Keywords

adverse drug event; healthcare system; national; multimorbidity; multiple; polypharmacy; referral; hospital.

### INTRODUCTION

The presence of several chronic illnesses in a single individual, termed multimorbidity, is a common occurrence in the majority of developed countries,<sup>1</sup> including Spain.<sup>2</sup> Although it particularly affects the older population, this problem is also present at other stages of life, including childhood.<sup>3</sup>

Recent studies have revealed the existence of patterns of multimorbidity that consist of systematically associated clinical conditions.<sup>2</sup> Such patterns evolve and worsen over the course of a patient's life, and reflect clinical situations that cut across individual medical specialties established by healthcare systems.<sup>2</sup>

The consequences of this complex reality for a healthcare system in which the majority of illnesses are chronic and affect the older and frailer portion of the population include polypharmacy (that is, the simultaneous and prolonged prescription of multiple medications to a single individual),<sup>4</sup> and repeated referrals for specialised care.<sup>5</sup>

These 'natural' consequences may have associated risks that are often unanticipated and insufficiently analysed, and ultimately compromise the health of the patient. For example, it has been evidenced that polypharmacy significantly increases the risk of inappropriate prescription and adverse drug events (ADEs).<sup>6</sup> In addition, care of the same

patient by different specialists has been shown to carry a risk of fragmented care, with frequent failures of the communication among professionals that is essential for evaluating and monitoring the patient's therapeutic regimen.<sup>7,8</sup>

Because of its high frequency and its consequences for patients in terms of therapeutic safety, this complex reality (patients with multimorbidity, polypharmacy, and under the care of different specialists) justifies new studies to improve understanding and awareness of this scenario. To the study's knowledge, none of the studies that have analysed this issue have taken place in a healthcare system where the family physician serves as the entry point to the system and provides continuous care for the patient.<sup>9</sup>

This study aims to analyse the influence of these factors (multimorbidity, polypharmacy, and multiple referrals) on the frequency of ADEs, as an indicator of therapeutic safety, in the context of a national healthcare system.

### METHOD

This was a multicentre observational study of patients treated at seven urban primary care centres in Zaragoza, Spain. Selection of centres to participate in this study was conducted based on the following quality inclusion criteria: (a) centres with computerised records for all appointments

**A Calderón-Larrañaga**, PhD, researcher;  
**B Poblador-Plou**, MPH, researcher;  
**A Prados-Torres**, MD, PhD, senior researcher, Aragón Health Sciences Institute (IACS), IIS Aragón, Miguel Servet University Hospital, University of Zaragoza, Spain. **F González-Rubio**, MD, GP, Aragón Health Sciences Institute (IACS), IIS Aragón, South Delicias Health Centre, Zaragoza, Spain. **Luis A Gimeno-Feliu**, MD, PhD, GP, Aragón Health Sciences Institute (IACS), IIS Aragón, San Pablo Health Centre, University of Zaragoza, Spain. **JM Abad-Díez**, MD, PhD, health inspector, Aragón Health Sciences Institute (IACS), IIS Aragón, Department of Health Wellbeing and Family, D.G. Planning and Assurance,

Government of Aragón, Zaragoza, Spain.

#### Address for correspondence

Amaia Calderón-Larrañaga, Hospital Universitario Miguel Servet. Hospital General, 2º Pl [antiguas consultas], Paseo Isabel La Católica 1–3, 50009 Zaragoza, Spain.

E-mail: acalderon.iacs@aragon.es

Submitted: 25 May 2012; Editor's response: 10 July 2012; final acceptance: 7 August 2012.

#### ©British Journal of General Practice

This is the full-length article (published online 26 Nov 2012) of an abridged version published in print. Cite this article as: **Br J Gen Pract 2012; DOI: 10.3399/bjgp12X659295**

## How this fits in

Patients with multimorbidity and polypharmacy, and under the care of different specialties, are now the rule rather than the exception. These conditions make patients' management and treatment difficult and may threaten their therapeutic safety. The results of this study demonstrate that multimorbidity is strongly related to the occurrence of adverse drug events, insofar as it requires the intervention of multiple specialties and the prescription of multiple medications.

and with more than 2 years' experience using this system by all physicians and nurses; (b) those with less than 20% of uncoded episodes; (c) those with less than 15% of notes (for example, prescription) listed in uncoded episodes; (d) those with less than 10% of prescriptions linked to uncoded episodes; (e) those with an average number of diagnoses higher than 3.5; and (f) those with less than 10% of patients with no diagnostic information.

All patients from the selected centres aged  $\geq 14$  years were included in the study if they were seen at least once during 2008 by their family physician and were assigned to the same doctor on 31 December of the same year. Information was extracted from primary care electronic medical records and the Aragón pharmacy database. Written consent by patients was not needed, since the work is based on the analysis of anonymous data contained in previously existing databases.

For each of the patients included in the study, the following variables were extracted from the record: age, sex, diagnostic episodes coded according to the International Classification of Primary Care (ICPC),<sup>10</sup> visits to the family physician, and referrals to specialists made by the family physician during 2008. The variable 'number of different specialties' was generated by adding all different specialties to which the patient was referred by their family physician during the study year, excluding internal referrals within the primary care setting (paediatrics, nursing, physical therapy, social work, dentistry, and midwifery).

Among the tools commonly used to measure and characterise multimorbidity is the Adjusted Clinical Groups System® (ACG), which is used to classify patients into 106 homogeneous categories as a function of clinical (diagnostic), demographic (age and sex), and need-for-care (frailty) variables obtained from the electronic

medical record.<sup>11</sup> To reduce the number of ACG categories to a more practical level for analysis, those categories that group patients with similar levels of multimorbidity are aggregated by the system into so-called resource utilisation bands (RUB 1 = healthy, RUB 2 = low morbidity, RUB 3 = moderate morbidity, RUB 4 = high morbidity, and RUB 5 = very high morbidity).<sup>12</sup> Consequently, the system also assigns a RUB category to each patient.

From the pharmacy database, detailed information was extracted about the medications dispensed to the study population from the pharmacy offices in Aragón, excluding those medications administered at the hospital (for example, antineoplastic drugs, antiretroviral drugs, blood coagulation factors, immunostimulating interferons). Specifically, information was extracted about the prescribed and dispensed active ingredients coded according to the Anatomical, Therapeutic, Chemical (ATC) Classification System, as well as the month and year of dispensation. This methodology allowed the variable 'patient with polypharmacy' to be constructed, defined in the present study as a person who received six or more medications with different active compounds in at least 1 month of the study year. For this variable, categories V (Various) and Y (Effects and Accessories) from the ATC classification were excluded because these categories group products outside the strict definition of medications.

The dependent variable 'patient with at least one ADE' was generated based on the presence of at least one episode coded with the ICPC code A85 (Adverse Drug Effect; Correct Dose) in the patient's electronic medical record.

A descriptive analysis of the study variables was performed based on frequency calculations.  $\chi^2$  tests were used to determine independence between the presence of ADEs and the rest of the variables. To this end, continuous variables were categorised as follows: age (14–17, 18–34, 35–44, 45–54, 55–64, 65–69, 70–74, 75–79, 80–84, and  $\geq 85$  years), number of different specialties (0, 1–3, 4–6, and  $>6$ ), and number of visits to the family physician (0, 1–9, 10–20, 21–30, and  $>30$ ). Bivariate and multivariate logistic regression models were used to quantify the associations obtained from the independence tests. In this case, the continuous variables were introduced into the models, to maximise the use of the available information. Statistical analysis was performed using the program STATA (version 11).

**Table 1. Distribution of patients with at least one adverse drug event according to demographic variables, level of multimorbidity, and health services use**

Variable	Population (n = 79 089)	Presence of at least one ADE (n = 692), n (%)	95% CI of percentage	P-value
<b>Age, years</b>				
14–17	2059	16 (0.78)	0.40 to 1.16	<0.001
18–34	19 600	87 (0.44)	0.35 to 0.54	
35–44	12 456	76 (0.61)	0.47 to 0.75	
45–54	12 188	92 (0.75)	0.60 to 0.91	
55–64	12 347	136 (1.1)	0.92 to 1.29	
65–69	5193	74 (1.42)	1.10 to 1.75	
70–74	4970	75 (1.51)	1.17 to 1.85	
75–79	4717	67 (1.42)	1.08 to 1.76	
80–84	3206	43 (1.34)	0.94 to 1.74	
≥85	2348	26 (1.11)	0.68 to 1.53	
<b>Sex</b>				
Male	34 487	224 (0.65)	0.56 to 0.73	<0.001
Female	44 602	468 (1.05)	0.95 to 1.14	
<b>RUB</b>				
Healthy	9552	0 (0)	0	<0.001
Low morbidity	22 542	43 (0.19)	0.13 to 0.24	
Moderate morbidity	43 768	460 (1.05)	0.96 to 1.15	
High morbidity	3008	158 (5.25)	4.46 to 6.05	
Very high morbidity	219	31 (14.16)	9.53 to 18.78	
<b>Number of different specialties</b>				
0	45 297	237 (0.52)	0.46 to 0.59	<0.001
1–3	32 966	429 (1.3)	1.18 to 1.42	
4–6	811	25 (3.08)	1.89 to 4.27	
>6	15	1 (6.67)	6.40 to 19.73	
<b>Number of family physician visits</b>				
0	2698	28 (1.04)	0.66 to 1.42	<0.001
1–9	61 137	352 (0.58)	0.52 to 0.64	
10–20	12 171	234 (1.92)	1.68 to 2.17	
21–30	2169	56 (2.58)	1.91 to 3.25	
>30	914	22 (2.41)	1.41 to 3.40	
<b>Polypharmacy<sup>a</sup></b>				
Yes	19 666	350 (1.78)	1.59 to 1.96	<0.001
No	59 423	342 (0.58)	0.51 to 0.64	

RUB = resource utilisation band.<sup>12</sup> <sup>a</sup>Six or more different active compounds in at least 1 month.

## RESULTS

Of the 79 089 patients studied, 692 had at least one ADE during the study period. As seen in Table 1, in which the distribution of patients with ≥1 ADE is described according to the different categories of the study variables, the majority of these patients were female, were aged 70–74 years old, and had a very high level of multimorbidity, polypharmacy, a high frequency of family physician visits (that is, 21–30 annual visits), and a high number of referrals to different specialties (that is, six or more specialties).

While the bivariate analysis demonstrated statistically significant associations between the risk of ADE and all the independent variables studied (Table 2), the multivariate analysis (Table 3) identified the following variables as risk factors in descending order of effect size: level of multimorbidity [odds ratio [OR] Veryhigh/Low = 45.26; ORHigh/Low = 17.58; ORModerate/Low = 4.25], polypharmacy [OR = 1.34], female sex [OR = 1.31], number of different specialties [OR = 1.20], and number of visits to the primary care physician [OR = 1.01]. Age, however, did not show statistical significance [OR = 1.00; 95% confidence interval = 0.996 to 1.005].

## DISCUSSION

### Summary

This study demonstrates the existence of a latent problem in the context of a national healthcare system in which the primary care physician acts as the entry point into the system and has the assigned function of monitoring the overall health of the patient. As the clinical situation of the patient becomes more complex and requires the intervention of different specialists, the likelihood of a lack of coordination among professionals and potential interactions among prescribed medications could favour the occurrence of undesirable effects, such as ADEs. The results of this study indicate that for every new specialty that participates in the care process, the probability that a patient will suffer an ADE increases by 12–28%, even after adjusting for known ADE risk factors such as age, sex, polypharmacy, frequency of primary care physician visits, and the burden of morbidity itself. While some factors such as age, sex, and level of multimorbidity have a direct relationship with the disease severity and clinical situation of the patient,<sup>13–15</sup> the undesirable effects of other factors, such as polypharmacy, frequency of family physician visits, and referrals to specialists, can be minimised. This reduction can be accomplished through new models of

**Table 2. Bivariate analysis of the risk of adverse drug events**

Factors	OR	P-value	95% CI
Age	1.020	<0.001	[1.016 to 1.024]
Sex: female/male	1.622	<0.001	[1.382 to 1.903]
<b>RUB</b>			
Healthy	—	—	—
Low morbidity	Reference		
Moderate morbidity	5.558	<0.001	[4.064 to 7.600]
High morbidity	29.007	<0.001	[20.660 to 40.728]
Very high morbidity	86.278	<0.001	[53.196 to 139.933]
Number of different specialties	1.623	<0.001	[1.528 to 1.722]
Number of visits to family physician	1.061	<0.001	[1.054 to 1.068]
Polypharmacy <sup>a</sup> : yes/no	3.130	<0.001	[2.694 to 3.636]

OR = odds ratio. RUB = resource utilisation band.<sup>12</sup> <sup>a</sup>Six or more different active compounds in at least 1 month.

**Table 3. Multivariate analysis of the risk of adverse drug events**

Factors	OR	P-value	95% CI
Age	1.001	0.811	[0.96 to 1.005]
Sex: female/male	1.307	0.001	[1.110 to 1.538]
<b>RUB</b>			
Healthy	—	—	—
Low morbidity	Reference		
Moderate morbidity	4.246	<0.001	[3.079 to 5.855]
High morbidity	17.577	<0.001	[12.229 to 25.265]
Very high morbidity	45.264	<0.001	[26.977 to 75.948]
Number of different specialties	1.195	<0.001	[1.116 to 1.280]
Number of visits to family physician	1.013	0.008	[1.003 to 1.023]
Polypharmacy <sup>a</sup> : yes/no	1.344	0.003	[1.106 to 1.634]

OR = odds ratio. RUB = resource utilisation band.<sup>12</sup> <sup>a</sup>Six or more different active compounds in at least 1 month.

eventually prescribed medication to a single patient during the study year; an aspect that underlies the occurrence of ADEs.<sup>7,8,23</sup> This variable does not include care received by professionals other than the family physician, either within the primary care setting or in other settings such as an emergency room or hospital. Neither does it include referrals among specialists or care at private centres.

It should also be noted that the polypharmacy variable does not include medications administered at a hospital or over-the-counter drugs.

### Comparison with existing literature

The presence of various chronic illnesses in a single patient is currently the rule rather than the exception. However, clinical care continues to be structured and organised to treat a single health problem at a time or, worse yet, to treat the various illnesses that a single patient has as if they were independent of each other and also isolated from the individual who suffers from them.<sup>24</sup> In fact, in the Spanish healthcare system, a considerable proportion of pharmaceutical prescriptions originate at the level of specialised care,<sup>25,26</sup> where it could be argued that the concept of the chief complaint takes priority over the overall health of the patient. In a recent hospital-based study of patients with polypharmacy, a lack of consideration of the medications that the patient was taking at the time of admission was responsible for up to 52.7% of medication errors.<sup>27</sup>

Most likely, one of the principal structural factors that makes clinical and therapeutic follow-up of the patient difficult for the group of professionals who provide care is related to the availability and adequate use of responsive and uniform information systems for the different levels of care.<sup>28,29</sup> Therefore, using a single electronic medical record or reinforcing the training of professionals in the use of available information tools would be beneficial steps.

Moreover, strengthening the necessary fluid and constant dialogue among professionals at different levels of care requires that organisational elements facilitate such dialogue. There are reports in the literature of interventions that yielded greater reduction of ADEs, including endowing hospital professionals with the specific function of reconciling medications,<sup>30</sup> or having geriatrics specialists evaluate frail, older patients.<sup>31</sup> However, one of the most effective measures for decreasing ADEs, and therefore improving the safety of the

### Funding

The study was funded by grant PI081581 from the Carlos III Health Institute and the Program for the Incorporation of Research Groups into the Spanish Health System (EMER 07/020).

### Ethical approval

Written consent by patients was not needed since the work is based on analysis of anonymous data contained in previously existing databases. The study is framed within a project that was favourably evaluated by the Clinical Research Ethics Committee of Aragon (CEICA).

### Provenance

Freely submitted; externally peer reviewed.

### Competing interests

The authors have declared no competing interests.

### Discuss this article

Contribute and read comments about this article on the Discussion Forum:  
<http://www.rcgp.org.uk/bjgp-discuss>

professional practice, increased availability of adequate informative tools, or other improvement interventions.<sup>16,17</sup> Results from this study suggest that the effect of age on the occurrence of ADEs might disappear when the variable level of multimorbidity is considered.

### Limitations of the study

Various limitations warrant prudent interpretation of the results of this study. The first is related to the result variable selected. Although ADEs are a good indicator of the safety of care (among the 10 leading causes of mortality worldwide,<sup>18</sup> and, on occasion, surpassing the cost of treatment of the baseline illness<sup>19</sup>), other indicators related to care, communication, diagnosis, or health management should also be considered and may offer a wider view of deficiencies in the care provided to patients with multimorbidity. However, it should be noted that, according to the 2008 APEAS study of patient safety in primary care performed by the Spanish Ministry of Health,<sup>20</sup> 47.8% of the adverse events detected in the primary care environment are due to medications,

The information about the occurrence of ADEs used in this study comes from an active registry of ADEs by physicians. Despite currently constituting the principal source of information for identifying areas of improvement in medication-related patient safety, this registry only includes 5–10% of the actual aggregate incidence of ADEs.<sup>21</sup> However, it is known that recorded ADEs tend to be those that involve a greater threat to the health of the patient.<sup>22</sup>

Importantly, the number of different specialties is an approximation of the number of different physicians who

care being given, consists of enhancing and strengthening the natural role of the primary care physician as a 'medication reconciler'.<sup>32</sup> Whenever feasible, the family physician is ideally placed to conduct an appropriate pharmacologic review of the patient, which can include asking for the removal of medications that are of little use, redundant, not indicated, or contraindicated.<sup>33</sup>

Finally, it should not be forgotten that a large gap currently exists, on the part of professionals, in the availability of clinical guidelines and protocols that guide the management of patients with multimorbidity.<sup>34</sup> Physicians frequently find themselves deciding whether to apply criteria that, while adequate for each illness that a patient has, are not appropriate when the diseases are considered together.<sup>4</sup> Finding solutions to this problem has become a critical priority.

#### **Implications for research and practice**

Further studies are required to shed light on the causal pathway between multimorbidity and increased risk of adverse events. For example, research should address whether the existence of gaps that disrupt the continuity of care has undesirable consequences related to patient safety.

Longitudinal studies following patients with multimorbidity over their life course would enable better capture of the incidence of ADEs, avoiding underestimation resulting from the potential time lag between contacting health services and the

occurrence of an adverse event.

Other research lines following from this study include: examining ADEs in relation to different therapeutic groups such as analgesics, cardiovascular medications, or antidepressants; determining the influence of healthcare providers; and studying other possible adverse events such as major trauma, suicide, or falls.

The results of this study demonstrate that multimorbidity is strongly related to the occurrence of ADEs, insofar as it requires the intervention of multiple specialties and the prescription of multiple medications.

As indicated by Starfield *et al* a decade ago,<sup>35</sup> it is necessary, now more than ever, to design strategies that encourage a review of the individual's health problems in their totality, rather than examining each of the patient's illnesses individually. This approach is important, as a result of the following factors: (1) the presence of concomitant chronic illnesses, which is most common in older people but also present at other stages of life; (2) frequent interactions between illnesses and medications or among medications that should not be forgotten or ignored; and (3) the fact that the repercussions of not taking such an approach greatly impact the healthcare system and can be devastating for the health of the patient.

Although this problem is complex, it is not intractable, and the scientific community is beginning to offer sufficient knowledge to be able to develop a solution.

## REFERENCES

1. Marengoni A, Angleman S, Melis R, et al. Aging with multimorbidity: a systematic review of the literature. *Ageing Res Rev* 2011; **10**(4): 430–439.
2. Prados-Torres A, Poblador-Plou B, Calderon-Larranaga A, et al. Multimorbidity patterns in primary care: interactions among chronic diseases using factor analysis. *PLoS One* 2012; **7**(2): e32190.
3. van den Akker M, Buntinx F, Metsemakers JF, et al. Multimorbidity in general practice: prevalence, incidence, and determinants of co-occurring chronic and recurrent diseases. *J Clin Epidemiol* 1998; **51**(5): 367–375.
4. Tinetti ME, Bogardus ST Jr, Agostini JV. Potential pitfalls of disease-specific guidelines for patients with multiple conditions. *N Engl J Med* 2004; **351**(27): 2870–2874.
5. Starfield B, Lemke KW, Herbert R, et al. Comorbidity and the use of primary care and specialist care in the elderly. *Ann Fam Med* 2005; 3(3): 215–222.
6. Gandhi TK, Weingart SN, Borus J, et al. Adverse drug events in ambulatory care. *N Engl J Med* 2003; **348**(16): 1556–1564.
7. Hajjar ER, Hanlon JT, Sloane RJ, et al. Unnecessary drug use in frail older people at hospital discharge. *J Am Geriatr Soc* 2005; **53**(9): 1518–1523.
8. Green JL, Hawley JN, Rask KJ. Is the number of prescribing physicians an independent risk factor for adverse drug events in an elderly outpatient population? *Am J Geriatr Pharmacother* 2007; **5**(1): 31–39.
9. The European study of referrals from primary to secondary care. Concerned Action Committee of Health Services Research for the European Community. *Occas Pap R Coll Gen Pract* 1992; **15**(6): 1–75.
10. Lamberts H, Wood M. ICPC: *International classification of primary care*. Oxford: Oxford University Press, 1987.
11. Starfield B, Weiner J, Mumford L, Steinwachs D. Ambulatory care groups: a categorization of diagnoses for research and management. *Health Serv Res* 1991; **26**(1): 53–74.
12. Johns Hopkins Bloomberg School of Public Health. *The Johns Hopkins ACG® System. Reference manual, version 8.2*. Baltimore: The Johns Hopkins University, 2008. <http://www.ensolution.se/upl/files/14429.pdf> [accessed 19 Oct 2012].
13. Onder G, Pedone C, Landi F, et al. Adverse drug reactions as cause of hospital admissions: results from the Italian Group of Pharmacoepidemiology in the Elderly (GIFA). *J Am Geriatr Soc* 2002; **50**(12): 1962–1968.
14. Field TS, Gurwitz JH, Harrold LR, et al. Risk factors for adverse drug events among older adults in the ambulatory setting. *J Am Geriatr Soc* 2004; **52**(8): 1349–1354.
15. Evans RS, Lloyd JF, Stoddard GJ, et al. Risk factors for adverse drug events: a 10-year analysis. *Ann Pharmacother* 2005; **39**(7–8): 1161–1168.
16. Routledge PA, O'Mahony MS, Woodhouse KW. Adverse drug reactions in elderly patients. *Br J Clin Pharmacol* 2004; **57**(2): 121–126.
17. Tierney WM. Adverse outpatient drug events — a problem and an opportunity. *N Engl J Med* 2003; **348**(16): 1587–1589.
18. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. *JAMA* 1998; **279**(15): 1200–1205.
19. Johnson JA, Bootman JL. Drug-related morbidity and mortality. A cost-of-illness model. *Arch Intern Med* 1995; **155**(18): 1949–1956.
20. Ministerio de Sanidad y Consumo. Estudio APEAS. *Estudio sobre la seguridad de los pacientes en atención primaria de salud*. Madrid: Ministerio de Sanidad y Consumo, 2008.
21. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. *Drug Saf* 2006; **29**(5): 385–396.
22. Gonzalez-Rubio F, Calderon-Larranaga A, Poblador-Plou B, et al. Underreporting of recognized adverse drug reactions by primary care physicians: an exploratory study. *Pharmacoepidemiol Drug Saf* 2011; **20**(12): 1287–1294.
23. Lim EC, Seet RC. Too many cooks spoil the broth. *Acad Med* 2007; **82**(5): 474.
24. Starfield B. Threads and yarns: weaving the tapestry of comorbidity. *Ann Fam Med* 2006; **4**(2): 101–103.
25. Perez GS, Millas RJ, Lopez Zuniga MC, et al. [Analysis of the induced prescription in a primary care region]. *Rev Calid Asist* 2010; **25**(6): 321–326.
26. Ruiz D, V, Unzueta ZL, Fernandez UJ, et al. [Induced prescription in primary health care in area Bilbao]. *Aten Primaria* 2002; **29**(7): 414–420.
27. Delgado SO, Nicolas PJ, Martinez L, et al. [Reconciliation errors at admission and departure in old and polypharmaceutical patients. Prospective, multicentre randomised study]. *Med Clin (Barc)* 2009; **133**(19): 741–744.
28. Sanfelix-Gimeno G, Peiro S, Meneu R. [Pharmaceutical prescription in primary care. SESPAS report 2012]. *Gac Sanit* 2012; **26**(suppl 1): 41–45.
29. Forster AJ, Jennings A, Chow C, et al. A systematic review to evaluate the accuracy of electronic adverse drug event detection. *J Am Med Inform Assoc* 2012; **19**(1): 31–38.
30. Rozich JD, Howard RJ, Justeson JM, et al. Standardization as a mechanism to improve safety in health care. *Jt Comm J Qual Saf* 2004; **30**(1): 5–14.
31. Schmader KE, Hanlon JT, Pieper CF, et al. Effects of geriatric evaluation and management on adverse drug reactions and suboptimal prescribing in the frail elderly. *Am J Med* 2004; **116**(6): 394–401.
32. Starfield B. New paradigms for quality in primary care. *Br J Gen Pract* 2001; **51**(465): 303–309.
33. Delgado SO, Anoz JL, Serrano FA, Nicolas PJ. [Conciliation in medication]. *Med Clin (Barc)* 2007; **129**(9): 343–348.
34. Fortin M, Dionne J, Pinho G, et al. Randomized controlled trials: do they have external validity for patients with multiple comorbidities? *Ann Fam Med* 2006; **4**(2): 104–108.
35. Starfield B, Lemke KW, Bernhardt T, et al. Comorbidity: implications for the importance of primary care in 'case' management. *Ann Fam Med* 2003; **1**(1): 8–14.